Pedro Barata, MD, MSc, FACP, discusses the goals of the NRG Oncology Semiannual Meeting taking place February 15-17, 2024.
The NRG Oncology Semiannual Meeting takes place from February 15 to 17, 2024, and serves as a hub where clinicians and researchers can meet and collaborate on the latest findings and practices in the oncology field.
Pedro Barata, MD, MSc, FACP, genitourinary oncology and clinical researcher, highlights NRG as "one of the most cooperative groups out there" when it comes to providing a space for oncologists to discuss questions and problems.
Here, Barata, a member of the Young Investigators Committee and Genitourinary Committee, discusses the goals and importance of the semiannual meeting.
Transcription:
0:05 | NRG, it’s one of the most important cooperative groups out there. Basically, what that means is a number of physicians and researchers get together on a regular basis and put together and try to develop concepts that ultimately will help patients. We try to answer questions that are relevant to patients, in this case diagnosed with many cancers. It’s an organization [that] has, you know, actually has the ability to get together colleagues and experts from different specialties, including radiation oncology, urology, medical, oncology, imaging, etc. Their role in helping moving science forward, you know, for the treatment of cancer, it's super, super important and has been for a long time.
0:58 | I think NRG, it's organized the way we know it for 10 years in a row, and it has been played a very important role in the management of advanced tumors, across solid tumors, but their role in in in academic research, it's fantastic.
In Real-World Analyses, Apalutamide Delivers Quicker Responses in Prostate Cancer
June 15th 2024Benjamin Lowentritt, MD, discussed findings from real-world analyses looking at enzalutamide or abiraterone vs apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
MOST Study Shows High Rates of Disease Progression in Low/Intermediate-Risk MF Over 4 Years
June 14th 2024MOST study shows high rates of disease progression in low/intermediate-risk myelofibrosis over 4 years, with the rate increasing over time. This offers valuable insight for a patient group with limited prior data.
Read More
Successes With T-DXd and the Need for Continued Research in Brain Metastasis
June 13th 2024In an interview with Targeted Oncology, Sarah Sammons, MD, discussed an analysis of the DESTINY-Breast03 trial, highlighting the need for further research on trastuzumab deruxtecan in other breast cancer subtypes and solid tumors with brain metastases.
Read More
Early Data Shows Axi-Cel’s Potential in Treating R/R Primary and Secondary CNS Lymphomas
June 13th 2024Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.
Read More